11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.

他克莫司患者中有11.7％的患者出现ACR70反应，而米唑瑞滨患者则没有。

youdao

This was also true of the ACR50 response (27.2% versus 2.0%). In addition, 11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.

这也是真正的美国风湿病学会标准的50%的反应率（27.2%对2.0%）。另外，11.7%的他克莫司治疗组病人获得了美国风湿病学会标准的70%的反应率，而咪唑立宾组无一达到。

youdao

This was also true of the ACR50 response (27.2% versus 2.0%). In addition, 11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.

这也是真正的美国风湿病学会标准的50%的反应率（27.2%对2.0%）。另外，11.7%的他克莫司治疗组病人获得了美国风湿病学会标准的70%的反应率，而咪唑立宾组无一达到。

youdao